339 related articles for article (PubMed ID: 28631712)
1. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
Demura TA; Revazova ZV; Kogan EA; Adamyan LV
Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
[TBL] [Abstract][Full Text] [Related]
2. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
[TBL] [Abstract][Full Text] [Related]
3. Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell Lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate Treatment: A Systematic Immunohistochemical Evaluation.
Courtoy GE; Donnez J; Marbaix E; Barreira M; Luyckx M; Dolmans MM
Gynecol Obstet Invest; 2018; 83(5):443-454. PubMed ID: 29227976
[TBL] [Abstract][Full Text] [Related]
4. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
5. [Ulipristal acetate (Esmya): a selective modulator of progesterone receptors, new treatment of uterine fibromatosis].
Nisolle M; Closon F; Firquet A; Top M; Pintiaux A
Rev Med Liege; 2014 Apr; 69(4):220-5. PubMed ID: 24923103
[TBL] [Abstract][Full Text] [Related]
6. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
7. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
8. The place of selective progesterone receptor modulators in myoma therapy.
Donnez J; Donnez O; Courtoy GE; Dolmans MM
Minerva Ginecol; 2016 Jun; 68(3):313-20. PubMed ID: 26930390
[TBL] [Abstract][Full Text] [Related]
9. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
Brazert M; Korman MP; Pawelczyk LA
Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
[TBL] [Abstract][Full Text] [Related]
10. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth.
Yoshida S; Ohara N; Xu Q; Chen W; Wang J; Nakabayashi K; Sasaki H; Morikawa A; Maruo T
Semin Reprod Med; 2010 May; 28(3):260-73. PubMed ID: 20414849
[TBL] [Abstract][Full Text] [Related]
11. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
13. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
14. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract][Full Text] [Related]
15. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
16. Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells.
Ciarmela P; Carrarelli P; Islam MS; Janjusevic M; Zupi E; Tosti C; Castellucci M; Petraglia F
Reprod Sci; 2014 Sep; 21(9):1120-5. PubMed ID: 25001022
[TBL] [Abstract][Full Text] [Related]
17. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
18. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.
Palaia I; Del Negro V; Fracassi A; Schiavi M; Di Donato V; Fischetti M; Muzii L; Benedetti Panici P
Gynecol Endocrinol; 2020 Jul; 36(7):660-661. PubMed ID: 31878806
[TBL] [Abstract][Full Text] [Related]
20. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
